Humana Inc vs Lithium Americas Corp — how do they compare? Humana Inc trades at $437.75 (market cap $47.61B), while Lithium Americas Corp trades at $2.39 (market cap $876.06M). The key difference: Humana Inc is far larger — about 54.3× Lithium Americas Corp's market cap, and Humana Inc pays a 0.89% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Lithium Americas Corp for 27 Days on average.
| HUM | LAC | |
|---|---|---|
Market Cap | $47.61B | $876.06M |
Volume | 1,827,332 | 9,397,178 |
Sector | Health | Basic Materials |
52-Week High | $409.85 | $10.05 |
52-Week Low | $163.67 | $2.36 |
Typical Hold Time | 53 Days | 27 Days |
Enterprise Value | $54.97B | $1.21B |
Dividend Yield | 0.89% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
Lithium Americas (LAC) trades at $2.41, down 5.12% on the day, reflecting ongoing market pressure despite recent earnings beats. The stock shows mixed signals with bearish technical indicators but bullish analyst sentiment, with 7 buy ratings and a $4.00 consensus price target. The company remains in development phase with no current revenue, reporting negative EBITDA of $51.80M for 2025, but has secured substantial financing to advance its Thacker Pass lithium project.
LAC presents a high-risk, high-reward opportunity as it transitions from development to execution. The primary catalyst is successful commercialization of Thacker Pass, which could drive significant rerating, but investors face substantial execution risk, lithium price volatility, and continued cash burn until production begins. Analyst optimism contrasts with current financial performance, creating a speculative investment case.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →